- Home
- GO vs ARVN Comparison
GO vs ARVN Comparison
Compare GO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GO
- ARVN
- Stock Information
- Founded
- GO 1946
- ARVN 2015
- Country
- GO United States
- ARVN United States
- Employees
- GO N/A
- ARVN N/A
- Industry
- GO Food Chains
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- GO Consumer Staples
- ARVN Health Care
- Exchange
- GO Nasdaq
- ARVN Nasdaq
- Market Cap
- GO 1.6B
- ARVN 1.4B
- IPO Year
- GO 2019
- ARVN 2018
- Fundamental
- Price
- GO $15.68
- ARVN $17.77
- Analyst Decision
- GO Hold
- ARVN Strong Buy
- Analyst Count
- GO 11
- ARVN 12
- Target Price
- GO $18.00
- ARVN $58.82
- AVG Volume (30 Days)
- GO 2.1M
- ARVN 1.1M
- Earning Date
- GO 02-25-2025
- ARVN 02-11-2025
- Dividend Yield
- GO N/A
- ARVN N/A
- EPS Growth
- GO N/A
- ARVN N/A
- EPS
- GO 0.51
- ARVN N/A
- Revenue
- GO $4,263,465,000.00
- ARVN $263,399,999.00
- Revenue This Year
- GO $13.11
- ARVN N/A
- Revenue Next Year
- GO $8.53
- ARVN $1.63
- P/E Ratio
- GO $30.72
- ARVN N/A
- Revenue Growth
- GO 9.03
- ARVN 235.54
- 52 Week Low
- GO $13.60
- ARVN $16.61
- 52 Week High
- GO $29.19
- ARVN $51.51
- Technical
- Relative Strength Index (RSI)
- GO 40.51
- ARVN 44.33
- Support Level
- GO $15.80
- ARVN $17.19
- Resistance Level
- GO $16.36
- ARVN $20.38
- Average True Range (ATR)
- GO 0.76
- ARVN 1.38
- MACD
- GO -0.12
- ARVN 0.08
- Stochastic Oscillator
- GO 7.80
- ARVN 30.77
About GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. Its flexible buying model allows them to offer quality, name-brand opportunistic products at prices generally 40% to 70% below those of conventional retailers. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.